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anti-programmed cell death protein-ligand 1 (PD-L1), and anti-cytotoxic T lymphocyte
antigen-4 (CTLA-4) monoclonal antibodies, are approved for the treatment of some
types of advanced cancer. Their main treatment-related side-effects are immune-
related adverse events (irAEs), especially thyroid dysfunction and hypophysitis.
Hypoparathyroidism, on the contrary, is an extremely rare irAE.
Objectives
The aim of the study was to investigate the etiology of autoimmune hypoparathyroidism
in a lung cancer patient treated with pembrolizumab, an anti-PD-1.
Methods
Calcium-sensing receptor (CaSR) autoantibodies, their functional activity, Ig
subclasses and epitopes involved in the pathogenesis of autoimmune
hypoparathyroidism were tested.
Results
The patient developed hypocalcemia after 15 cycles of pembrolizumab. Calcium levels
normalised with oral calcium carbonate and calcitriol and no remission of hypocalcemia
was demonstrated during a nine-month follow-up. The patient was found to be positive
for CaSR-stimulating antibodies, of IgG1 and IgG3 subclasses, that were able to
recognize functional epitopes on the receptor, thus causing hypocalcemia.
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Context: Immune checkpoint inhibitors (ICIs), as anti-programmed cell death protein-1 23 
(PD-1), anti-programmed cell death protein-ligand 1 (PD-L1), and anti-cytotoxic T 24 
lymphocyte antigen-4 (CTLA-4) monoclonal antibodies, are approved for the treatment of 25 
some types of advanced cancer. Their main treatment-related side-effects are immune-26 
related adverse events (irAEs), especially thyroid dysfunction and hypophysitis. 27 
Hypoparathyroidism, on the contrary, is an extremely rare irAE.  28 
Objectives: The aim of the study was to investigate the etiology of autoimmune 29 
hypoparathyroidism in a lung cancer patient treated with pembrolizumab, an anti-PD-1. 30 
Methods: Calcium-sensing receptor (CaSR) autoantibodies, their functional activity, Ig 31 
subclasses and epitopes involved in the pathogenesis of autoimmune hypoparathyroidism 32 
were tested. 33 
Results: The patient developed hypocalcemia after 15 cycles of pembrolizumab. Calcium 34 
levels normalised with oral calcium carbonate and calcitriol and no remission of 35 
hypocalcemia was demonstrated during a nine-month follow-up. The patient was found to 36 
be positive for CaSR-stimulating antibodies, of IgG1 and IgG3 subclasses, that were able 37 
to recognize functional epitopes on the receptor, thus causing hypocalcemia. 38 
Conclusion: The finding confirms that ICIs therapy can trigger, amongst other 39 
endocrinopathies, hypoparathyroidism which can be caused by pathogenic autoantibodies. 40 






Immune checkpoint inhibitors (ICIs) are monoclonal antibodies directed against T cells 42 
surface receptors involved in immune regulation such as cytotoxic T lymphocyte antigen-43 
4 (CLTA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein-44 
ligand 1 (PD-L1) (1-3). ICIs, now used against a variety of solid tumors, are also significant 45 
because they induce a broad spectrum of toxicities collectively referred to as immune-46 
related adverse events (irAEs) that can affect any organ or tissue (3). The endocrine glands 47 
appear to be preferentially targeted sites resulting in autoimmune endocrinopathies that are 48 
akin to the primary form of the autoimmune disease. Examples include thyroid dysfunction, 49 
which is common during anti-PD-1 blockade, pituitary dysfunction, which is more often 50 
found during anti-CTLA-4 blockade, and type 1 diabetes, which is more prevalent 51 
following anti-PD-L1 therapy (3). Other endocrinopathies, such as adrenalitis, central 52 
diabetes insipidus or hypoparathyroidism, have rarely been described during ICIs treatment 53 
(4,5). 54 
In rare cases, primary hypoparathyroidism and hypoparathyroidism in the context of 55 
autoimmune polyendocrine syndrome type 1 (APS 1), has been related to the presence of 56 
antibodies that activate the calcium-sensing receptor (CaSR), a molecule that controls 57 
serum calcium levels via PTH secretion from the parathyroid gland (6,7). Such stimulating 58 
antibodies may result in abnormally low PTH levels, even when serum calcium levels are 59 
lower than optimal and need to be raised. Other reports implicate antibody-mediated 60 
cytoxicity or T cell infiltration of the parathyroid as immunological causes of 61 
hypoparathyroidism (8-11). With respect to hypoparathyroidism as an irAE, the few 62 





reported cases (2,12-14) suggest that the disorder can be due to parathyoid inflammation 63 
(12) or CaSR activating antibodies (2). 64 
The aims of the current study were to report a lung cancer patient treated with 65 
pembrolizumab, an anti-PD-1, who had developed hypoparathyroidism with symptomatic 66 
hypocalcemia, and to investigate the aetiology of the endocrine disorder including the 67 
presence of activating antibodies to the CaSR, their epitopes and IgG subclasses. 68 





PATIENT AND METHODS 69 
Case presentation 70 
A 52-year-old man was treated with pembrolizumab (anti-PD-1) at 2 mg/kg every three 71 
weeks, starting from September 2017, for his metastatic lung adenocarcinoma. ICIs therapy 72 
was continued for 21 cycles (14 months) and interrupted in November 2018 due to diarrhea 73 
which ceased after a few days. In February 2019, the patient was admitted to ER for recent 74 
appearance of confusion, drowsiness, muscle weakness, and cramps. He had suffered from 75 
epilepsy and depression for 15 years and was treated with topiramate, gabapentin, and 76 
citalopram. Blood tests revealed hyponatremia and hypocalcemia, thus the patient was 77 
referred to our Endocrine Unit for further evaluation.  78 
The patient did not have history of autoimmune diseases, neck surgery or neck irradiation. 79 
No evidence for metasteases in the neck region were apparent at the latest CT scan.  Family 80 
history was also negative for hypocalcemic disorders and autoimmune diseases. 81 
At physical examination, the patient was euvolemic, his blood pressure was in the normal 82 
range (125/80 mmHg), and Chvostek and Trousseau signs were both positive. To rule out 83 
endocrine causes of hyponatremia, blood tests for basal pituitary hormones, thyroid 84 
function, electrolytes, urine analysis with urinary sodium excretion, urine osmolality, 85 
plasma osmolality, were performed.  To evaluate adrenal reserve, a cosyntropin test (250 86 
μg intramuscular injection) was carried out. The results of analytes and antibody tests are 87 
given in Table 1. These showed a normal adrenal and thyroid function. Severe 88 
hyponatremia was confirmed and accompanied by elevated sodium excretion and urine 89 
osmolality. Hypocalcemia was associated with inappropriately normal levels of PTH, low 90 
levels of 25-hydroxy vitamin D and normal magnesium values. A revision of the clinical 91 





records of the patient demonstrated that,  two months before starting ICIs,  calcium  and 92 
PTH levels were in the normal range (25 pg/mL and 9.2 mg/dL, respectively) and that a 93 
mild hypocalcemia (7.8 mg/dL) had appeared after the 15th dose (at 11 months) of 94 
pembrolizumab and had worsened over time, even after ICIs withdrawal (Figure 1A). PTH 95 
levels decreased overtime remaining detectable (Figure 1B). The patient was treated with 96 
intravenous calcium gluconate infusions and switched to oral calcium carbonate (1 g per 97 
day) and calcitriol (1 μg per day) which normalized his serum calcium concentration within 98 
a few days.  99 
It also became apparent that mild hyponatremia (132 mEq/L) had developed after three 100 
cycles of pembrolizumab, worsened over time and became severe (120 mEq/L) after ICIs 101 
withdrawal (Figure 1C). Adrenal insufficiency and hypothyroidism were ruled out thus 102 
pointing to a syndrome of inappropriate antidiuretic hormone secretion (SIADH) as the 103 
cause of hyponatremia. SIADH was likely due to a multifactorial origin including the  104 
oncologic disease and concomitant therapy with citalopram and other drugs for epilepsy. 105 
After fluid restriction and citalopram withdrawal an improvement of  hyponatremia was 106 
observed (Figure 1C). 107 
The patient was regularly followed at our Endocrine Unit after ICIs withdrawal for an 108 
additonal nine months. However, despite treatment with oral calcium carbonate plus 109 
calcitriol, no remission of hypocalcemia was demonstrated during this period (Figure 1A).  110 
Informed consent for biochemical, in vitro studies and publication was obtained from the 111 
patient. 112 
CaSR immunoprecipitation assays 113 





CaSR immunoprecipitation assays used to detect CaSR antibodies were undertaken as 114 
detailed elsewhere (15). Briefly, human embryonic kidney 293 (HEK293) cells were 115 
transiently transfected with pcCaSR-FLAG. Cell extract containing expressed CaSR-116 
FLAG protein was then prepared and stored at -80°C. GammaBind® Sepharose beads (50-117 
µl samples) (GE Healthcare, Little Chalfont, UK) were mixed with sera at a 1:100 dilution 118 
in immunoprecipitation buffer, and incubated at 4°C for 1 h. The beads and IgG complexes 119 
were collected and incubated with cell extract containing CaSR-FLAG protein for 16 h at 120 
4°C. The bead-IgG-CaSR-FLAG protein complexes were collected and subjected to SDS-121 
PAGE and immunoblotting using anti-FLAG® M2-Peroxidase Conjugate (Sigma-Aldrich, 122 
Poole, UK) and an ECL™ Western Blotting Analysis System (GE Healthcare).  The 123 
densitometry of bands on developed films resulting from immunoprecipitated CaSR-FLAG 124 
protein was performed in a Bio-Rad GS 690 Scanning Densitometer with Multi-Analyst 125 
Software (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). A CaSR antibody index for 126 
each serum sample was calculated as the densitometry value of the tested serum/mean 127 
densitometry value of 12 control sera. The upper normal limit for the assay was calculated 128 
using the mean CaSR antibody index + 3 SD of 12 controls.  129 
CaSR peptide ELISAs 130 
CaSR peptide ELISAs to identify CaSR antibody binding sites were done as detailed 131 
previously (16). The peptides (Cambridge Peptides, Birmingham, UK) used represented 132 
amino acid residues 41-69, 114-126, 171-195, 344-358, and 374-391 of the CaSR 133 
sequence. In brief, 20 ng of the required peptide were applied to the wells of a 96-well 134 
microtiter plate overnight at 4°C. Plate wells were blocked with blocking buffer (PBS 135 
containing 0.1% Tween 20 and 3% BSA) for 30 min at 37°C, and washed with PBS 136 





containing 0.1% Tween 20. Patient and control sera were added to wells at a 1:100 dilution 137 
and incubated at room temperature for 1 h before washing. Antibody binding was detected 138 
using anti-human IgG conjugated to alkaline phosphatase (Sigma-Aldrich, Poole, U.K.) 139 
and alkaline phosphatase substrate SIGMAFAST p-Nitrophenyl phosphate (Sigma-140 
Aldrich) with OD values read at 405 nm. A CaSR antibody index for each serum sample 141 
was calculated as the OD405 of the tested serum/mean OD405 value of 20 control sera. 142 
The upper normal limits for the ELISAs were calculated using the mean CaSR antibody 143 
index + 3 SD of 20 controls.  144 
To estimate CaSR antibody titres, the patient’s serum was analysed at dilutions of 1:100 to 145 
1:10,000. Titres were defined as the serum dilution at which antibody binding was detected 146 
above the upper limit of normal for the CaSR peptide ELISA. 147 
CaSR antibody purification 148 
Initially, IgG was isolated from sera using protein G Sepharose 4 Fast Flow (GE 149 
Healthcare) affinity chromatography, according to the manufacturer’s instructions. 150 
Antibodies against a specific CaSR peptide (41–69, 114–126, 171–195, 344-358 and 374-151 
391) were isolated by affinity chromatography using a CarboxyLink Immobilization Kit 152 
(Thermo Fisher Scientific, Waltham, MA, USA). All purified antibodies were dialysed, 153 
concentrated, and stored at –20°C at 10 mg/ml. 154 
CaSR antibody IgG subclass, functional affinity and specificity  155 
To determine the IgG subclass of purified CaSR antibodies, anti-human IgG1, IgG2, IgG3, 156 
and IgG4 alkaline phosphatase conjugates (SouthernBiotech, Birmingham, AL) were 157 
applied as the secondary antibody in CaSR peptide ELISAs. 158 





To determine functional affinities, purified CaSR antibodies were incubated at non-159 
saturating dilutions with a range of concentrations (0–1000 nM) of the required CaSR 160 
peptide for 30 min before analysis in the appropriate CaSR peptide ELISA. Functional 161 
affinity was expressed as the concentration of peptide that blocked 50% of antibody 162 
binding in CaSR peptide ELISAs. 163 
To evaluate CaSR antibody specificity, purified CaSR antibodies were preabsorbed at a 164 
non-saturating dilution with a 200X M excess of the required CaSR peptide before analysis 165 
in CaSR peptide ELISAs. Antibody binding following preabsorption was expressed as a 166 
percentage of antibody binding without preabsorption.  167 
Intracellular inositol-1-phosphate accumulation assay  168 
As described elsewhere (16), the stimulatory effects of Ca2+ on HEK293 cells expressing 169 
the CaSR (HEK293-CaSR) were measured by assessing intracellular inositol-1-phosphate 170 
(IP1) accumulation. Monolayer HEK293-CaSR cells were cultured in 24-well plates before 171 
washing with serum-free medium and Ca2+-free assay buffer containing 10 mM lithium 172 
chloride. For investigating CaSR antibody effects, cells were preincubated for 10 min at 173 
37°C with patient CaSR antibodies or control IgG at a 1:100 dilution, and then stimulated 174 
with 1.5 mM calcium chloride for 60 min at 37°C. HEK293-CaSR cells without 175 
preincubation with IgG were also included as controls. Subsequently, cells were lysed for 176 
30 min at 37°C with 50 μl of 2.5% IP-One ELISA Kit Lysis Reagent (CIS Bio International, 177 
Gif-sur-Yvette, France). The accumulation of intracellular IP1 was assessed using an IP1 178 
ELISA Kit (CIS Bio International), according to the manufacturer’s protocol. 179 
RESULTS 180 





Detection of patient’s CaSR autoantibodies  181 
Immunoprecipitation assays detected CaSR antibodies in the patient’s serum with a CaSR 182 
antibody index of 61.3 (Figure 2) compared with the upper limit of normal for the assay of 183 
2.73 (Figure 2). To identify the binding sites of the patient’s CaSR antibodies, previously 184 
characterised epitopes (6,16) at CaSR amino acid residues 41–69, 114–126, 171–195, 344-185 
358 and 374-391 were tested in ELISAs against the patient’s serum. Antibody reactivity 186 
was detected against epitopes 41-69, 114-126, 171-195 but not against CaSR peptides 344-187 
358 and 374-391 (Figure 3). Antibody titres against each relevant epitope were investigated 188 
in ELISAs. Titres were 1:1000 for antibodies against epitope 41–69 and 114-126, and 189 
1:5000 against epitope 171–195  (Table 2). 190 
Determination of CaSR antibody IgG subclass, functional affinity, and specificity 191 
Following purification of the patient’s CaSR antibodies, ELISAs were used to analyse their 192 
IgG subclass. The results indicated that antibodies against CaSR epitopes 41–69 and 171–193 
195 were of IgG1 subclass, and that antibodies against  114–126 were subtype IgG3 (Table 194 
2). The functional affinities of the patient’s CaSR antibodies were analysed in ELISAs. 195 
The results showed that functional affinities ranged from 10-8 to 10-7 M (Table 2). The 196 
specificity of the patient’s CaSR autoantibodies was analysed by preabsorption of the 197 
purified antibodies with CaSR peptides representing identified epitopes. Any effects upon 198 
CaSR antibody binding were then assessed in ELISAs. The results showed that binding 199 
was only significantly reduced by preabsorption with the CaSR peptide recognised as the 200 
antibody epitope; no detectable cross-reactivity between different CaSR antibodies was 201 
evident (Table 2). 202 
Analysis of CaSR antibody functional effects 203 





The effect of the patient’s CaSR antibodies on receptor activity was analysed by 204 
preincubation of HEK293-CaSR cells with CaSR antibody samples prior to stimulating 205 
with Ca2+. Intracellular IP1 accumulation was then measured as the indicator of CaSR-206 
stimulation. Autoantibody-stimulation of the CaSR would be expected to increase 207 
intracellular IP1 levels shifting the inositol-1-phosphate-calcium curve leftwards and 208 
decreasing the set-point that is normal for the receptor. 209 
The results showed that preincubation of HEK293-CaSR cells with antibodies against 210 
CaSR epitopes 114–126 and 171-195 gave a statistically significant increase in IP1 211 
accumulation upon Ca2+ stimulation at 0.5, 1.5, and 3.0 mM, compared with Ca2+ 212 
stimulation alone; *P values were < 0.05, one-way ANOVA (Figure 4). 213 
Both antibody types were therefore considered as having CaSR-activating activity. In 214 
contrast, no effect on IP1accumulation was evident from pre-treatment with antibodies 215 
against the CaSR epitope 41-69 (Figure 4).  216 
Previous cases of ICI-induced hypoparathyroidism 217 
The previously reported cases of ICI-induced hypoparathyroidism are summarised in Table 218 
3. In two cases, the pathomechanism of hypoparathyroidism was not determined (13,14) 219 
Inflammation of the parathyroid was the cause in one case (12), and the presence of CaSR-220 
activating antibodies in another (2). 221 
DISCUSSION 222 
In recent years, therapeutic antibodies have been introduced into clinical practice in order 223 
to target key regulators of peripheral immune-tolerance, namely anti-CTLA-4, anti-PD-1, 224 
and anti-PD-L1, with the goal of activating the immune system against cancer cells (1). An 225 





undesirable, but somewhat expected, effect of immunotherapy is the triggering of 226 
autoimmune diseases, referred to as irAEs (3,17). Some irAEs are very common, such as 227 
thyroid dysfunction (accounting for about 10% during anti-PD-1 therapy) and hypophysitis 228 
(accounting for up to 12% during anti-CTLA-4 therapy), but others such as 229 
hypoparathyroidism, adrenalitis and diabetes insipidus are extremely rare (2-4,12-14,17).  230 
ICIs induce a general inflammatory response that can facilitate the development of irAEs 231 
through several mechanisms. These mechanisms, which are not mutually exclusive, 232 
include an increase in T cell activity against antigens shared by tumor and healthy tissues, 233 
and an elevation of pre-existing autoantibody levels or the development of novel antibody 234 
responses. In addition, the production of pro-inflammatory cytokines such as IL-17 may 235 
occur. Finally, another possible mechanism is when a direct binding of an anti-CTLA-4 236 
antibody to CTLA-4  - when expressed ectopically on cells other than T lymphocytes- 237 
occur causing a complement-mediated inflammation as described in ICI-induced 238 
hypophysitis (1,18).   239 
To date, only four cases of hypoparathyroidism following cancer immunotherapy have 240 
been described and are summarised in Table 3 (2,12-14). However, the disease mechanism 241 
although suspected in terms of an autoimmune response, has not been determined in all 242 
four patients. In one case, a mechanism of parathyroid inflammation was suggested (12) 243 
and in a second, the presence of CaSR activating antibodies was confirmed (2). 244 
An autoimmune aetiology of hypoparathyroidism is rare (19), although it is a major 245 
manifestation of autoimmune polyendocrine syndrome type 1 (APS1) (16). 246 
In autoimmune cases of hypoparathyroidism, T cells are the most likely mediators causing 247 
a mononuclear infiltration found in the parathyroid (8). Indeed, CaSR specific cytotoxic T 248 





cells have been reported in 82.2% of idiopathic hypoparathyroid patients (10,11). However, 249 
an equivalent destruction of the gland could be achieved by antibody-mediated cytoxicity 250 
which has also been proposed as a pathomechanism (9). In addition, CaSR activating 251 
antibodies that are able to reduce the secretion of PTH from the parathyroids - thus keeping 252 
serum calcium levels artificially low - have been reported in patients with 253 
hypoparathyroidism (7,16)  254 
In accordance with the results reported by Piranavan and colleagues (2), the serum of the 255 
patient here described,  was markedly positive for CaSR antibodies. In addition, we found 256 
that these CaSR antibodies recognised the epitopes 41–69, 114–126, and 171–195  on the 257 
receptor (13). Interestingly, the recognition of these epitopes was previously reported in 258 
100%, 31%, and 38% of 16 APS1 patients, respectively (16). So they appear to be common 259 
and major binding sites for autoantibodies against the CaSR, but different from the most 260 
frequent CaSR T cell epitopes that were discovered in hypoparathyrid patients by Mahtab 261 
and co-workers (11). 262 
The finding that the patient’s CaSR antibodies were of IgG1 and IgG3 subclasses is in 263 
agreement with the previous findings (16). They have, therefore, the potential to bind 264 
complement and be involved in antibody-mediated cytotoxicity (9,20), but these immune 265 
mechanisms were not evaluated here. 266 
The increase of IP1 accumulation in a cell line expressing the CaSR upon treatment with 267 
the patient’s purified CaSR antibodies, demonstrated the activating role of the antibodies 268 
against CaSR epitopes 114-126 and 171-195. Activation of the CaSR caused a leftward 269 
shift of the inositol-1-phosphate-calcium curve and a decrease of the normal set-point of 270 
the CaSR. This would cause a reduction of PTH secretion even at lower than optimal serum 271 





calcium levels, thus causing hypocalcemia. With regard to the function of the CaSR, 272 
epitope 114-126 forms part of the molecule in which point mutations or deletions cause 273 
autosomal dominant hypoparathyroidism by increasing sensitivity to calcium (21,22). 274 
Antibody binding to this epitope could favor the active conformation of the receptor 275 
leading to lowering of PTH secretion even when calcium levels are below optimum. This 276 
action resembles that observed with stimulating antibodies to the TSH receptor in Graves’ 277 
disease (23). 278 
Site-directed mutagenesis and molecular models have shown that epitope 171-195 is 279 
crucial for Ca2+ binding (21,24,25) thus it is easy to conceive of how antibody binding to 280 
this part of the CaSR could adversely affect the interaction of calcium ions with this binding 281 
site. 282 
Antibodies against the CaSR epitope at 41-69, did not affect the function of the receptor. 283 
Such neutral binding autoantibodies that do not have any detectable functional effects have 284 
also been reported against the TSH receptor in patients with autoimmune thyroid disease 285 
(26), although they may be capable of exacerbating the autoimmune response via other 286 
antigen-driven mechanisms. 287 
In conclusion, the findings in this study suggest that CaSR-activating antibodies are able 288 
to contribute to ICI-induced hypoparathyroidism by reducing the secretion of PTH from 289 
the parathyroid thus keeping serum calcium levels artificially low.  290 
Other immune mechanisms that could occur simultaneously and result in destruction of the 291 
parathyroid, including T cells and cytotoxic antibodies, were not investigated in this study.  292 
Overall, it is important that clinicians are aware of the potential risk for hypocalcemia 293 





associated with the use of immunotherapies as, in general, irAEs are unpredictable in 294 
presentation and timing (27). 295 
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LEGENDS TO FIGURES  440 
Figure 1 441 
Biochemical and hormonal test results during immunotherapy and after ICI-withdrawal. 442 
(A) Total serum calcium; (B) PTH; and (C) sodium. The normal ranges are shaded.  443 
Figure 2 444 
Detection of CaSR antibodies in the patient’s serum. Sera from the patient and healthy 445 
controls (n = 12) were tested for binding to the CaSR using a CaSR immunoprecipitation 446 
assay. The results are shown for sera tested in duplicate in three experiments. The upper 447 
limit of normal for the CaSR immunoprecipitation assay (mean CaSR antibody index + 3 448 
SD of 12 control sera) was a CaSR antibody index of 2.73. The CaSR antibody index of 449 
the patient’s serum sample was 61.3, indicating positivity for CaSR antibodies. 450 
Figure 3 451 
Identification of CaSR antibody binding sites. Sera from the patient and 20 healthy controls 452 
were evaluated in ELISAs for antibodies against CaSR peptides 41–69, 114–126, 171–195, 453 
344-358, and 374-391. The results are shown for sera tested in duplicate in three 454 
experiments. The upper limits of normal (mean CaSR antibody index + 3 SD of 20 control 455 
sera) were 1.84, 1.93, 2.83, 1.75, and 2.02 for the 41-69, 114-126, 171-195, 344-358, and 456 
374-391 peptide ELISAs, respectively. The patient’s serum had antibody indices of 30.1, 457 
10.6, 15.4, 1.10, and 1.23 for the 41-69, 114-126, 171-195, 344-358, and 374-391 peptide 458 
ELISAs, respectively, indicating binding sites at three different epitopes. 459 
Figure 4 460 





Detection of CaSR-stimulating activity of the patient’s CaSR antibodies. Intracellular 461 
IP1(IP1) accumulation in HEK293-CaSR cells was measured in response to stimulation by 462 
0.5-5 mM Ca2+ after they were preincubated with the patient’s CaSR antibody samples or 463 
healthy control antibody (n = 12). Cells without preincubation with antibody were included 464 
in experiments. Intracellular IP1accumulation was measured using an IP-One ELISA, and 465 
the results expressed as: percentage inhibition of IP1-HRP binding = [1 - IP1-HRP binding 466 
in stimulated cells/IP1-HRP binding in unstimulated cells] x 100. Increasing intracellular 467 
levels of IP1were reflected by an increase in the percentage inhibition of IP1-HRP binding 468 
in the IP-One ELISA. The results are shown for the patient’s CaSR antibodies tested in 469 
four experiments. Preincubation with antibodies against epitopes 114-126 and 171-195 470 
increased the levels of IP1 accumulation significantly in HEK293-CaSR cells at 471 
concentrations of 0.5-3.0 mM Ca2+; *P values were < 0.05, one-way ANOVA, indicating 472 
that they had receptor-stimulating activity. 473 





Table 1 Biochemical and hormonal features at first evaluation, three months after anti-1 











Sodium 120 135-145 mEq/L 
Potassium 3.85 3.5-5.1 mEq/L 
Calcium 6.2 8.6-10.2 mg/dL 
Ionised calcium 0.8 1.13-1.32 mEq/L 
Phosphorus 3.7 2.5-4.5 mg/dL 
Magnesium 2.2 1.7-2.5 mg/dL 
Albumin 4.6 3.5-5 g/dL 
Creatinin 0.7 0.7-1.2 mg/dL 
Urea 14 10-50 mg/dL 
Uric acid  2.6 3.5-7 mg/dL 
Glucose 76 74-109 mg/dL 
Cosyntropin test 
    Cortisol (Time 0’) 9.8  
    Cortisol (Time 30’) 29.3  
    Cortisol (Time 60’) 38.3  
ACTH 12 <50 ng/L 
PTH 18 8-40 pg/mL 
25-hydroxyvitamin D 12 > 30 µg/L 
FSH 1.4 1.3-19.5 mIU/mL 
LH 4.8 1.4-12.7 mIU/mL 
Testosterone 3.52 1.75-7.8 µg/L 
PRL 10.9 2-13 ng/mL male 
IGF-1 99 57-202 µg/L 
FT4 1.14 0.7-1.7 ng/dL 
TSH 1.4 0.4-4 mcIU/mL 
TgAb Negative <30 IU/mL 
TPOAb Negative <10 IU/mL 
Plasma osmolality 255 280-295 mOsm/Kg 
Urinary osmolality 250 300-800 mOsm/kg 
Urinary sodium excretion 70  54-190 mEq/L 
 5 
1Values outside the reference range are highlighted in bold type-face. 6 
7 
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1CaSR antibody titres were defined as the dilution of the patient’s serum at which antibody binding 
could still be detected above the upper limits of normal for the CaSR peptide ELISAs. 
2The functional affinity of purified CaSR antibodies was calculated as the concentration of the 
relevant CaSR peptide that blocked 50% of CaSR antibody binding in CaSR peptide ELISAs. 
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